Anlotinib (AL3818) plus pemetrexed in patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A single-arm, open-label, phase II study.
Yanna Zhang(China Electronics Technology Group Corporation), He Huang(Sun Yat-sen University), Xingyu Jiang(Sun Yat-sen University), Jiaqi Qiu(Sun Yat-sen University), Ting Wan(Guangzhou University of Chinese Medicine), Libing Song(Sun Yat-sen University), Lie Zheng(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Jihong Liu(Sun Yat-sen University), Li Han(Howard Hughes Medical Institute), Ying Xiong(Sichuan University), Jueming Chen(Guangzhou First People's Hospital), Yanling Feng(First Affiliated Hospital of Guangzhou Medical University), Jundong Li(University of Virginia)
Cited by 1
Related Papers
Feature Selection
|ACM Computing Surveys|2017|2.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Line Graph Neural Networks for Link Prediction
|IEEE Transactions on Pattern Analysis and Machine Intelligence|2021|235
Wnt5a induces and maintains prostate cancer cells dormancy in bone
|The Journal of Experimental Medicine|2018|223
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217